CVS Health Stock Is Moving Higher Monday: What's Going On?
CVS Health Stock Is Moving Higher Monday: What's Going On?
CVS Health's board now consists of 16 members in total. CVS Health said the appointments are aimed at improving financial and operational performance and driving long-term value.CVS Health Corporation (NYSE:CVS) shares are trading higher Monday after the company announced the addition of four new directors to its board. Here's what you need to know.
西維斯健康公司（紐交所：CVS）股票週一交易上漲，因該公司宣佈向董事會增加四位新董事。以下是您需要了解的情況。
What To Know: CVS Health has appointed four new members to its board including Larry Robbins, Leslie Norwalk, Guy Sansone and Doug Shulman. The appointments come as a result of discussions with activist investor Glenview Capital Management, a major stakeholder.
需要了解的事項：西維斯健康已任命四位新成員加入其董事會，包括Larry Robbins、Leslie Norwalk、Guy Sansone和Doug Shulman。這些任命是與激進投資者Glenview Capital Management進行討論的結果，後者是一家主要股東。
The new board members bring varied expertise. Norwalk will join the Health Services Committee, Sansone will join the Audit Committee and Shulman will join the Management Planning and Development Committee. Robbins, who is the CEO of Glenview, will also join the board.
新董事會成員擁有不同的專長。Norwalk將加入衛生服務委員會，Sansone將加入審計委員會，Shulman將加入管理規劃和發展委員會。Glenview的CEO Robbins也將加入董事會。
CVS Health's board now consists of 16 members in total. CVS Health said the appointments are aimed at improving financial and operational performance and driving long-term value.
西維斯健康的董事會現在總共有16名成員。西維斯健康表示，這些任命旨在提高財務和運營績效，實現長期價值。
"Adding four experienced thought leaders to our Board further sharpens our focus on executing against our strategy to build a world of health around every consumer, as we improve total cost of care and customer experience in health care," said David Joyner, president and CEO of CVS Health.
「向我們的董事會增加了四位經驗豐富的思想領袖進一步聚焦於執行我們的策略，圍繞每位消費者打造一個健康世界，同時我們改善醫療保健中的整體成本和客戶體驗。」西維斯健康的總裁兼首席執行官David Joyner表示。
In connection with the appointments, CVS Health and Glenview entered into a confidentiality agreement with customary provisions regarding confidentiality, standstill arrangements and other related matters. The details of this agreement are expected to be filed in a Form 8-K with the U.S. Securities and Exchange Commission.
與這些任命相關，西維斯健康和Glenview簽署了涉及典型保密規定、停滯安排以及其他相關事宜的保密協議。預計該協議的詳細內容將在8-k表格中向美國證券交易委員會提交。
"We welcome the opportunity to join the Board, roll up our sleeves and lock arms with the Board and leadership team to drive long-term, sustainable value through continued customer-centric offerings, commitment to compliance and quality, disciplined underwriting and risk management, aligned incentives, and optimal capital allocation," Robbins said.
「我們歡迎加入董事會的機會，共同努力、與董事會和領導團隊緊密合作，通過持續以客戶爲中心的產品、對合規和質量的承諾、紀律性承銷和風險管理、一致的激勵措施以及優化資本配置，創造長期可持續的價值。」Robbins表示。
"We appreciate the Board engaging with us on a cooperative basis that allows all energies to be productively dedicated towards further strengthening this iconic company."
「我們感謝董事會與我們合作基礎，使所有精力都能得以有效地用於進一步加強這傢俱有標誌性的公司。」
Following the board changes, Wells Fargo analyst Stephen Baxter upgraded CVS Health from Equal-Weight to Overweight, and adjusted the price target from $60 to $66.
在董事會變動之後，富國銀行分析師史蒂芬·巴克斯特（Stephen Baxter）將西維斯健康的評級從"Equal-Weight"升級爲"Overweight"，並將價格目標從60美元調整至66美元。
CVS Price Action: CVS Health shares were up 5.55% at $56.13 at the time of writing, according to Benzinga Pro.
西維斯健康股價表現：根據貝寧薩普（Benzinga Pro）的數據，在撰寫本文時，西維斯健康股價上漲了5.55%，達到56.13美元。
- Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
- 下一代研究中令人鼓舞的早期數據使得百時美施貴寶的CAR-T療法備受關注，特別是用於自身免疫性疾病。
Image Via Shutterstock.
圖片來自Shutterstock。
譯文內容由第三人軟體翻譯。
